Evome Medical Technologies Inc. (LNDZF)
| Market Cap | 301.24K -97.4% |
| Revenue (ttm) | 35.78M -16.3% |
| Net Income | -17.42M |
| EPS | -0.20 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,000 |
| Open | 0.000001 |
| Previous Close | 0.000001 |
| Day's Range | 0.000001 - 0.000001 |
| 52-Week Range | 0.000001 - 0.0060 |
| Beta | 2.22 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 25, 2026 |
About LNDZF
Evome Medical Technologies Inc. designs, develops, produces, and sells medical devices in the United States. The company was formerly known as Salona Global Medical Device Corporation and changed its name to Evome Medical Technologies Inc. in January 2024. The company is based in Shirley, New York. [Read more]
Financial Performance
In 2023, LNDZF's revenue was 62.63 million, an increase of 55.35% compared to the previous year's 40.31 million. Losses were -15.60 million, -18.21% less than in 2022.
Financial numbers in CAD Financial StatementsNews
Michael Dalsin Resigns as Chairman of the Board of Directors of Evome Medical Technologies
NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (“Evome”, the “Company”) (TSXV: EVMT) announced the resignation of Michael Dalsin as Chairman of the Board of Directors. M...
Evome Medical Technologies Provides Market Update
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) is providing an update to shareholders today.
Evome Medical Technologies Appoints Michael Dalsin as Chairman of the Board of Directors; Increases Size of Board to Six
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) announces the appointment of Michael Dalsin as Chairman of the Board of Directors. Kenneth Ka...
CLARIFICATION: Evome Medical Technologies Announces Significant Debt Restructuring
SHIRLEY, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) issued a press release on Monday, February 10, 2025 announcing the details of an amendment...
Evome Medical Technologies Announces Significant Debt Reduction and Restructuring
SHIRLEY, N.Y., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) has announced a significant reduction in its overall debt, strengthening its financial po...
Evome Medical Technologies Grants Restricted Stock Units to New Chief Operating Officer
SHIRLEY, N.Y., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) is pleased to announce that the Company's Board of Directors has approved the grant of 1,0...
Evome Medical Technologies Posts Third Quarter 2024 Results, Generates $424,000 in Adjusted EBITDA on Stable Revenues, Further Reduces Debt
Launches Evome Medical Products Distribution Company, Appoints Bill Garbarini Chief Operating Officer Adding Plan for a broader portfolio of Life Science Products Launches Evome Medical Products Distr...
Evome Medical Technologies Earnings release: Q3 2024
Evome Medical Technologies released its Q3 2024 earnings on November 25, 2024, summarizing the period's financial results.
Evome Medical Technologies Registration statement: Q3 2024
Evome Medical Technologies filed a registration statement on November 25, 2024, providing details about a securities offering with the SEC.
Evome Medical Technologies Registration statement: Q3 2024
Evome Medical Technologies filed a registration statement on November 25, 2024, providing details about a securities offering with the SEC.
Evome Medical Technologies Announces Results From Its Annual General and Special Meeting of Shareholders
SHIRLEY, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today announced the results from its annual general and special meeting of sha...
Evome Medical Technologies Earnings Call Transcript: Q2 2024
Q2 2024 saw strong revenue and profit growth in the core business, with positive adjusted EBITDA and significant debt reduction. Asset sales and a new white-labeling strategy are set to further improve financial health and drive growth in 2025.
Evome Medical Technologies Earnings release: Q2 2024
Evome Medical Technologies released its Q2 2024 earnings on August 19, 2024, summarizing the period's financial results.
Evome Medical Technologies Registration statement: Q2 2024
Evome Medical Technologies filed a registration statement on August 19, 2024, providing details about a securities offering with the SEC.
Evome Medical Technologies Registration statement: Q2 2024
Evome Medical Technologies filed a registration statement on August 19, 2024, providing details about a securities offering with the SEC.
Evome Medical Technologies Reviews Highlights of Low-CapEx Revenue Growth Plan
Posts updated corporate presentation to website Reminder: Conference call to be held on August 19 th to discuss Q2 2024 financial results SHIRLEY, N.Y., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical...
Evome Medical Technologies Reports Second Quarter 2024 Financial Results
SHIRLEY, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today reported financial results for the second quarter ended June 30, 2024, f...
Evome Medical Technologies Retains irlabs for Investor Relations Services
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) is pleased to announce it has entered into an agreement ("Agreement") with IR Labs I...
Evome Medical Technologies Transcript: Guidance
Significant turnaround achieved with cost cuts, asset sales, and new product launches driving revenue growth. Plans include further debt reduction, expansion into private physical therapy, and continued innovation, with positive financial momentum expected.
Evome Medical Technologies Press release: Guidance
Evome Medical Technologies issued a press release on June 4, 2024, disclosing material business information to investors.
Evome Medical Technologies Announces Update Call with CEO Mike Seckler for Tuesday, June 4, 2024; Provides Update on Strong Q2
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today provided details on preliminary estimated revenues and margins from April and ...
Evome Medical Technologies Announces Biodex Generated 100% Sales Growth Comparing April 2024 to January 2024, Plans to Shed Remaining Non-Core Units to Pay Off Remaining Acquisition Debt
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today reported continued progress on its turn-around plan. Evome has grown revenue at...
Evome Medical Technologies Earnings release: Q1 2024
Evome Medical Technologies released its Q1 2024 earnings on May 30, 2024, summarizing the period's financial results.
Evome Medical Technologies Registration statement: Q1 2024
Evome Medical Technologies filed a registration statement on May 30, 2024, providing details about a securities offering with the SEC.
Evome Medical Technologies Registration statement: Q1 2024
Evome Medical Technologies filed a registration statement on May 30, 2024, providing details about a securities offering with the SEC.